10 years ago

PrEP Biopharm Secures £21 Million for Respiratory Infection Prevention

  • PrEP Biopharm, a UK-based developer of respiratory infectious disease products, closed a £21 million Series A financing round led by hVIVO plc and Johnson & Johnson Innovation – JJDC, Inc., with participation from U.S.-based angel investors

  • The funds will be used to complete ongoing phase 2a development of PrEP-001, a nasally administered, broad-spectrum agent that leverages the innate immune system to prevent upper respiratory tract viral infections

  • PrEP Biopharm is developing and will market infectious disease products based on intellectual property licensed in from Janssen Sciences Ireland.

      • ProblemHealthcare

      "Millions of people suffer from colds and flus every year, and there are limited effective prevention options available. "

      Solution

      "PrEP-001 is a nasally administered drug that boosts the immune system to prevent upper respiratory tract viral infections. "

      Covered on